Drug Profile
Palivizumab biosimilar - BioXpress Therapeutics
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator BioXpress Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in Switzerland (IM, Injection)
- 20 Aug 2013 Preclinical trials in Respiratory syncytial virus infections in Switzerland (IM)